聚乙二醇化尿酸酶：撤回其欧洲市场授权是受欢迎的。 - Suppr | 超能文献

Pegloticase: withdrawal of its European marketing authorisation is welcome.

出版信息

Prescrire Int. 2017 Mar;26(180):71.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Pegloticase: withdrawal of its European marketing authorisation is welcome.聚乙二醇化尿酸酶：撤回其欧洲市场授权是受欢迎的。

Prescrire Int. 2017 Mar;26(180):71.

2

Methaemoglobinaemia and haemolysis following pegloticase infusion for refractory gout in a patient with a falsely negative glucose-6-phosphate dehydrogenase deficiency result.一名葡萄糖-6-磷酸脱氢酶缺乏检测结果为假阴性的患者在接受聚乙二醇化尿酸酶输注治疗难治性痛风后出现高铁血红蛋白血症和溶血。

Rheumatology (Oxford). 2014 Dec;53(12):2310-1. doi: 10.1093/rheumatology/keu346. Epub 2014 Sep 14.

3

Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.聚乙二醇尿酸酶（pegloticase），一种尿酸酶的聚乙二醇共轭物，用于痛风的潜在静脉治疗。

Curr Opin Investig Drugs. 2008 Apr;9(4):422-9.

4

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.聚乙二醇化尿酸酶是一种用于治疗对传统疗法难治的慢性痛风的重组尿酸酶，与输注相关的反应。

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200.

5

Pegloticase for treating refractory chronic gout.聚乙二醇尿酸酶用于治疗难治性慢性痛风。

Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475.

6

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.培戈洛酶治疗常规治疗难治性慢性痛风的长期安全性。

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.

7

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.接受培戈洛酶治疗慢性难治性痛风患者输注反应的频率、分布和免疫性质。

Arthritis Res Ther. 2017 Aug 17;19(1):191. doi: 10.1186/s13075-017-1396-8.

8

Pegloticase-Associated Hemolysis.聚乙二醇化尿酸酶相关溶血

Am J Ther. 2019 Sep/Oct;26(5):e622-e624. doi: 10.1097/MJT.0000000000000828.

9

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.多剂量聚乙二醇化尿酸酶（pegloticase）治疗痛风治疗失败患者后血浆尿酸水平的降低：一项II期随机研究的结果

Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810.

10

Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study.基于真实世界数据的培戈洛酶治疗痛风的应用模式：描述性多数据库队列研究。

BMJ Open. 2020 Dec 7;10(12):e041167. doi: 10.1136/bmjopen-2020-041167.

引用本文的文献

1

To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.要不要聚乙二醇化：纳米医学最常用成分聚乙二醇及其替代品的免疫特性。

Adv Drug Deliv Rev. 2022 Jan;180:114079. doi: 10.1016/j.addr.2021.114079. Epub 2021 Dec 10.

2

Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions.伪过敏输注反应猪模型的人体临床相关性

Biomedicines. 2020 Apr 8;8(4):82. doi: 10.3390/biomedicines8040082.